Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Enlaza Therapeutics is developing protein-based therapeutics that bind irreversibly to their target.
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. City Therapeutics is using very small cityRNAs to broaden the range of siRNA therapeutics.
The COP16 decision established a multilateral mechanism for digital sequence information (DSI) benefit-sharing. This Comment brings together insights from academia and commercial DSI researchers to assess what has been accomplished so far, identify remaining challenges and describe elements under discussion to support collective goals.
Breaking the cycle of institutional betrayal and the culture of silence requires decisive actions to promote transparency, accountability and supportive environments in both academia and industry.
Cultivated meat faces escalating intellectual property (IP) issues as the industry expands, including conventional patent rights, the private IP rights of animal breeders and the Convention on Biological Diversity.
With a newly marketed product in Japan and 10 years of clinical data, regenerative cell therapies promise new options for patients facing a choice between invasive surgery or blindness.
A new screen platform named DEFUSE (DEath FUSion Escape) enables high-throughput discovery of small molecule protein degraders. DEFUSE identified SKPer1, a molecule that works by inducing proximity between an oncogenic driver and an E3 ligase, opening new avenues for targeted protein degradation.
